External Beam and Nuclear Therapy of Medullary Thyroid Cancer

2021 ◽  
Vol 66 (1) ◽  
pp. 79-84
Author(s):  
I Pimonova ◽  
V. Krylov ◽  
P Isaev ◽  
T. Kochetova ◽  
E Borodavina
Keyword(s):  
Thyroid Cancer ◽  
Bone Metastases ◽  
Radionuclide Therapy ◽  
Medullary Thyroid Cancer ◽  
Combined Therapy ◽  
Somatostatin Analogs ◽  
Distant Metastases ◽  
Targeted Drugs ◽  
Medullary Thyroid ◽  
Peptide Receptor

The article reviews domestic and foreign literature on the use of radiation therapy in the treatment of medullary thyroid cancer. The possibilities of various radiation methods in the treatment of patients with distant metastases are shown. In addition to classical types of remote irradiation, data are presented on the possibilities of radionuclide therapy (peptide-receptor therapy with somatostatin analogs and radionuclide therapy with osteotropic drugs for bone metastases). Methods of combined therapy with the use of osteomodifying agents, targeted drugs and other methods are described, which make it possible to increase the effectiveness of treatment of patients with medullary thyroid cancer with bone metastases.

Is There a Role for Peptide Receptor Radionuclide Therapy in Medullary Thyroid Cancer?

2015 ◽  
Vol 40 (2) ◽  
pp. 123-127 ◽  
Author(s):  
Fernanda Vaisman ◽  
Paulo Henrique Rosado de Castro ◽  
Flavia Paiva Proença Lobo Lopes ◽  
Daniel Barretto Kendler ◽  
Cencita H.N. Pessoa ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Radionuclide Therapy ◽  
Medullary Thyroid Cancer ◽  
Peptide Receptor Radionuclide Therapy ◽  
Medullary Thyroid ◽  
Peptide Receptor

Serum Calcitonin May Falsely Estimate Tumor Burden in Chronic Hypercalcemia: A Case of Prostatic and Multiple Bone Metastases from Medullary Thyroid Cancer

Thyroid ◽  
2014 ◽  
Vol 24 (3) ◽  
pp. 599-603 ◽  
Author(s):  
Hee Kyung Kim ◽  
Woo Kyun Bae ◽  
Yoo Duk Choi ◽  
Hyun Jeong Shim ◽  
Jee Hee Yoon ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Bone Metastases ◽  
Medullary Thyroid Cancer ◽  
Tumor Burden ◽  
Serum Calcitonin ◽  
Medullary Thyroid ◽  
Multiple Bone Metastases

scholarly journals Comparison of 68Ga PET/CT to Other Imaging Studies in Medullary Thyroid Cancer: Superiority in Detecting Bone Metastases

2018 ◽  
Vol 103 (9) ◽  
pp. 3250-3259 ◽  
Author(s):  
Luciana Audi Castroneves ◽  
George Coura Filho ◽  
Ricardo Miguel Costa de Freitas ◽  
Raphael Salles ◽  
Raquel Ajub Moyses ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Bone Metastases ◽  
Medullary Thyroid Cancer ◽  
Imaging Studies ◽  
Medullary Thyroid ◽  
Pet Ct

Detection by SPECT-CT Scan with 99mTc-(V) DMSA of Bone Metastases in Patient with Medullary Thyroid Cancer

2011 ◽  
Vol 30 (6) ◽  
pp. 365-367
Author(s):  
A. De Bonilla-Damiá ◽  
C. Calvo-Morón ◽  
P.A. De la Riva-Pérez ◽  
R. Iglesias-Jerez ◽  
M. Molina-Mora ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Ct Scan ◽  
Bone Metastases ◽  
Medullary Thyroid Cancer ◽  
Medullary Thyroid

scholarly journals Efficacy of vandetanib in the treatment of medullary thyroid cancer: literature review and case report

2019 ◽  
Vol 9 (3) ◽  
pp. 38-48
Author(s):  
А. М. Mudunov ◽  
Yu. V. Alymov ◽  
I. S. Romanov ◽  
S. О. Podvyaznikov ◽  
А. V. Ignatova
Keyword(s):  
Clinical Trials ◽  
Thyroid Cancer ◽  
Tyrosine Kinases ◽  
Medullary Thyroid Cancer ◽  
Locally Advanced ◽  
Distant Metastases ◽  
Individual Characteristics ◽  
Medullary Thyroid ◽  
Mechanisms Of Carcinogenesis ◽  
Thyroid Malignancies

Medullary thyroid cancer (MTC) is a rare disorder that accounts for approximately 1.7 % of all thyroid malignancies. MTC is usually detected at early stages; however, approximately 10–15 % of patients are diagnosed with locally advanced MTC and distant metastases. Treatment of such patients is challenging due to biological characteristics of the disease and very few effective treatment approaches available. The investigation of mechanisms of carcinogenesis, as well as advances in pharmacology, allowed the development of a new group of targeted drugs, namely tyrosine kinases, which efficacy against progressive unresectable locally advanced or metastatic MTC has been demonstrated in multiple clinical trials. Vandetanib has been registered for MTC treatment in the Russian Federation. MTC is very rare, thus, each case of vandetanib use for its treatment is particularly interesting. Moreover, since the approval of this drug in 2011 by the U. S. Food and Drug Administration (FDA), new data on the clinical use of vandetanib have been accumulated. Importantly, clinical trials are usually well designed and conducted in near-ideal conditions, whereas the real conditions can be different and patients may have individual characteristics. Therefore, the aim of this study was to update the information on the efficacy and safety of vandetanib by retrospective analysis of available publications and to report a case of MTC treated with vandetanib.

Exceptionality of Distant Metastases in Node-Negative Hereditary and Sporadic Medullary Thyroid Cancer: Lessons Learned

2021 ◽  
Author(s):  
Andreas Machens ◽  
Kerstin Lorenz ◽  
Frank Weber ◽  
Henning Dralle
Keyword(s):  
Risk Factors ◽  
Thyroid Cancer ◽  
Lymph Node ◽  
Medullary Thyroid Cancer ◽  
Distant Metastases ◽  
Node Negative ◽  
Medullary Thyroid ◽  
Primary Tumor Size ◽  
Node Metastasis ◽  
Node Positive

Abstract Context Risk factors of lymph node and distant metastases have rarely been analyzed in hereditary and sporadic medullary thyroid cancer (MTC) using large genetic-clinical data sets. Objective This comprehensive investigation aimed to explore risk factors of lymph node and distant metastases and interdependencies between age at thyroidectomy, primary tumor size, lymph node metastasis and distant metastasis in patients with hereditary and sporadic MTC. Methods Comparative analyses of risk factors of metastasis, stratified by hereditary MTC (four mutational risk categories) and sporadic MTC. Results There were 1115 patients with hereditary MTC (307 patients) or sporadic MTC (808 patients). Age at thyroidectomy increased proportionately from 12.2, 22.7, 34.3, and 49.8 years for patients with decreasing mutational risk, as compared to 52.1 years for patients with sporadic MTC. Metastatic primary tumors overall were 10.7–19.4 mm larger in node-positive patients and 15.9–19.3 mm larger in distant metastatic patients at thyroidectomy than nonmetastatic tumors. Distant metastases were noted in 13–50% of node-positive vs. 0% of node-negative hereditary MTC, and in 23.5% of node-positive vs. 1.7% of node-negative sporadic MTC. In multivariable logistic regression analysis for sporadic MTC, lymph node metastasis contributed to distant metastasis (odds ratio 12.4) more than primary tumor size (odds ratios of 7.8, 5.5 and 2.4 for tumors measuring >60, 41–60 and 21–40 mm). Conclusions When thyroidectomy is performed before lymph node metastases have developed, distant metastases are exceptional, both in patients with hereditary MTC, irrespective of the level of mutational risk, and patients with sporadic MTC.

The Role of Radionuclide Therapy in Medullary Thyroid Cancer

2003 ◽  
Vol 89 (5) ◽  
pp. 560-562 ◽  
Author(s):  
Maria Rita Castellani ◽  
Alessandra Alessi ◽  
Giordano Savelli ◽  
Emilio Bombardieri
Keyword(s):  
Thyroid Cancer ◽  
Radionuclide Therapy ◽  
Medullary Thyroid Cancer ◽  
Medullary Thyroid

Safety of denosumab in patients with refractory differentiated thyroid cancer and advanced medullary thyroid cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e17578-e17578 ◽  
Author(s):  
Johanna Wassermann ◽  
Elise Mathy ◽  
Geraldine Lescaille ◽  
Marine Slim ◽  
Camille Buffet ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Bone Metastases ◽  
Differentiated Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Kinase Inhibitor ◽  
Calcium Supplementation ◽  
Osteonecrosis Of The Jaw ◽  
Treatment Benefit ◽  
Medullary Thyroid ◽  
Cervical Surgery

e17578 Background: Few data exist regarding the use of denosumab in patients with bone metastases from radioactive iodine (RAI) refractory differentiated thyroid cancer (DTC) and advanced medullary thyroid cancer (MTC). We aimed to describe adverse events of specific interest - osteonecrosis of the jaw (ONJ) and severe hypocalcemia - in this rare setting. Methods: We retrospectively reviewed the charts of all the patients treated with denosumab for bone metastases from RAI-refractory DTC and advanced MTC in our institution. All patients had a calcium measurement and a clinical and radiological dental screening before denosumab initiation. All patients without hypercalcemia received a calcium supplementation. We assessed associations between ONJ or severe hypocalcemia ( < 1.75mmol/L) and suspected risk factors by Fisher exact tests. Results: Between 2014 and 2018, 23 patients were treated with denosumab. Two-thirds of patients were male (n = 16), median age was 69 years (range 43-87). Histology was DTC and MTC in 19 (83%) and 4 (17%) patients, respectively. DTC patients had received a median cumulated dose (CD) of 300 mCi of RAI (range 100-700). Ten patients (43%) had at least one cervical surgery for recurrence or persistence, and 6 (26%) had cervical radiotherapy. Four patients had hypoparathyroidism before denosumab initiation. Two-thirds of patients ( n =15) received a tyrosine kinase inhibitor (TKI) in association with denosumab. The median duration of denosumab was 20 months (range 1-47). ONJ occurred in 6 patients (26%) and severe hypocalcemia in 3 patients (13%). Conclusions: Patients with RAI-refractory DTC and advanced MTC are at high risk of ONJ and severe hypocalcemia under denosumab treatment. Benefit/risk ratio should be highly weighted particularly when treatment is prolonged. Patients should be closely monitored for the risk of ONJ and hypocalcemia. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document